All In Biotech

Drug Trial Radar · NCT06418607

A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants

Phase 1, Open Label, Randomized, Single-center, 2-sequence, 2-period, 2 Treatment Single Dose Crossover Bioequivalence Study Comparing Venglustat Tablet Formulation (Test) to Hard Capsule Formulation (Reference)

Last checked: Nov 19, 2026Latest source record: May 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

65

Actual

Start

Jun 23, 2020

Primary completion

Jul 13, 2020

Study completion Jul 13, 2020

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the bioequivalent effect of venglustat in tablet and hard capsule form when give with water under fasting conditions. Also, to evaluate the safety and tolerability of a single dose tablet and hard capsule of venglustat (swallowed whole) under fasting conditions in healthy adult participants. The maximum duration for participants from screening is up to 47 days.

Conditions

  • Healthy Volunteers

Interventions

  • VenglustatDrug

    Pharmaceutical form:Tablet-Route of administration:Oral

  • VenglustatDrug

    Pharmaceutical form:Hard Capsule-Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration observed (Cmax) of venglustatTime frame: Multiple time points up to day 16
  2. Area under the plasma concentration versus time curve calculated from time zero to the real time (tlast) (AUClast) of venglustatTime frame: Multiple time points up to day 16
  3. Area under the plasma concentration versus time curve (AUC) of venglustatTime frame: Multiple time points up to day 16

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami Site Number : 8400001

    Miami, Florida

  • Prism Research Site Number : 8400002

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.